NCT00290953
Completed
Phase 2
A Double Blind, Randomized, Phase II-III Maintenance Study of SR48692 Versus Placebo in Patients With Extensive Stage Small Cell Lung Cancer Following a First Line Chemotherapy With Cisplatin + Etoposide
DrugsSR48692
Overview
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 432
- Locations
- 2
- Primary Endpoint
- - Overall survival (OS)
Overview
Brief Summary
To demonstrate an increase in overall survival for patients with newly diagnosed extended stage small cell lung cancer when treated with SR48692 versus placebo, after an initial response (complete or partial response or stable) to first line cisplatin plus etoposide.
Primary objective: comparison of overall survival between patients in the control arm and the meclinertant arm.
Secondary objectives: comparison of the progression free survival, the time to progression, the clinical benefit, the quality of life, the toxicity and safety between patients in the control arm and the meclinertant arm.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Pathological diagnosis: Histologically or cytologically proven SCLC.
- •Disease stage: extensive stage
- •Measurable disease by the RECIST criteria is required. Lesions that are present in previously irradiated area are non-measurable unless they have appeared or progressed since completion of the radiation.
- •Radiotherapy, if applicable, must have been completed at least 4 weeks before treatment under this protocol and the subject must have recovered from any acute toxicities of radiation.
- •Recovered from any surgical procedure(s).
- •Calculated creatinine clearance \> 55 ml/min using the Cockcroft-Gault formula: Cr Cl in ml/min = (140-age) X (weight in kg) X (1.0 for men or 0.85 for women) / (72 X serum Cr in mg/dl).
- •Total bilirubin \< two times the upper limit of the normal range at the institution and SGOT/AST \< two times the upper limit of normal unless liver metastases are present.
- •ANC \> 1.5 x 109/L and platelet count \> 100 x 109/L.
- •Age \>18 years.
- •Karnofsky Performance Status \> 70% .
Exclusion Criteria
- •Limited disease.
- •Symptomatic brain metastases: a patient with brain and/or leptomeningeal metastases on computer tomography (CT) or Magnetic Resonance Imaging (MRI) scan may be included only if he/she is asymptomatic on neurologic exam and is not receiving corticosteroid therapy to control symptoms.
- •Concurrent active cancer, including cancer stable on adjuvant therapy.
- •Prior immunotherapy, biological therapy or chemotherapy for SCLC.
- •Radiotherapy: Prior radiation to non-symptomatic or non-life-threatening sites.Prior radiation therapy to all potential indicator lesions. Prior radiation therapy to some but not all indicator lesions is allowed.
- •Class III or IV congestive heart failure according to the New York Heart Association Classification.
- •History of allergic reactions to appropriate diuretics or antiemetics (e.g., 5-HT3 antagonists) to be administered in conjunction with protocol-directed chemotherapy.
- •Uncontrolled intercurrent illness.
- •Lactating or pregnant women.
- •Received any investigational drug within 30 days before beginning treatment with study drug.
Outcomes
Primary Outcomes
- Overall survival (OS)
Secondary Outcomes
- - Toxicity and safety assessment using NCI CTC version 2.0
- - Progression Free Survival (PFS)
- - Time to Progression (TTP)
- - Clinical Benefit assessed by Performance Status and body weight
- - Quality of Life using the LCSS and EuroQoL validated instruments
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 3
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate CancerProstatic NeoplasmsNCT00744497Bristol-Myers Squibb1,930
Completed
Phase 2
Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus GemcitabineNon Small Cell Lung CancerNCT00753714Genzyme, a Sanofi Company124
Withdrawn
Phase 3
A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT01266811Centocor, Inc.
Completed
Phase 3
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck CancersCarcinoma, Squamous Cell of the Head and NeckNCT01166542Oncolytics Biotech167
Completed
Phase 2
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLCNon Small Cell Lung CancerNCT00743938Bristol-Myers Squibb141